• Users Online: 481
  • Print this page
  • Email this page
Year : 2021  |  Volume : 5  |  Issue : 2  |  Page : 105-109

Vaccine in response to COVID-19: Recent developments, challenges, and a way out

Department of Genetics, Indian Academy Degree College; Founder and CEO, GenLab BioSolutions Private Limited, Bengaluru, Karnataka, India

Correspondence Address:
Mr. Sameer Quazi
Department of Genetics, Indian Academy Degree College, Bengaluru, Karnataka; GenLab BioSolutions Private Limited, Bengaluru, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/bbrj.bbrj_166_20

Rights and Permissions

Severe acute respiratory syndrome coronavirus 2 proved to be disastrous as it affected a large population in the period of a few months. As the virus took hold in the world, health experts paced efforts to solve the unknown nature of this threat. Besides finding short-term and sudden relief, scientists directed their efforts to provide a long-term solution for an ensuing pandemic that influenced all areas of life in unprecedented ways. The subject matter of this research involves exploring the relevant literature regarding passive immunity in fight against the virus. It is expected that different vaccine platforms such as traditional recombinant protein, macromolecule DNA and mRNA, and nonreplicating and replicating viral vectors could be helpful if utilized properly. This article is going to discuss all these platforms and recent developments regarding the formulation of the vaccine. It is going to highlight the need for the production and distribution of the medicines along with challenges that are present in this task. The facts involving social, political, and economic aftermath would also be discussed in the current research. There is no doubt that biotechnology is going to provide a sound foundation to fight with upcoming health-related challenges. Along with the exploration of this fact, the article is going to prove a case for effective collaboration among all stakeholders such as government, academia, health sector, and civil society. The mechanism of collaboration would produce safety and efficacy data with the help of many volunteers, to speed up the distribution of multiple vaccine platforms to fight against COVID-19 and to strive for a better future.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded228    
    Comments [Add]    
    Cited by others 1    

Recommend this journal